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The monoterpene indole alkaloids (MIAs) are a valuable family of chemicals that include 
the anti-cancer drugs vinblastine and vincristine. These compounds are of global 
significance – appearing on the World Health Organization’s list of model essential 
medicines – but remain exorbitantly priced due to low in planta levels. Chemical 
synthesis and genetic manipulation of MIA producing plants such as Catharanthus 
roseus have so far failed to find a solution to this problem. Synthetic biology holds a 
potential answer, by building the pathway into more tractable organisms such as 
Saccharomyces cerevisiae. Recent work has taken the first steps in this direction by 
producing small amounts of the intermediate strictosidine in yeast.  In order to help 
improve on these titers, we aimed to optimize the early biosynthetic steps of the MIA 
pathway to the metabolite nepetalactol. We combined a number of strategies to create a 
base strain producing 11.4 mg/L of the precursor geraniol. We also show production of 
the critical intermediate 10-hydroxygeraniol and demonstrate nepetalactol production in 
vitro. We demonstrate that activity of the Iridiod synthase towards the intermediates 
geraniol and 10-hydroxygeraniol results in the synthesis of the non-productive 
intermediates citronellol and 10-hydroxycitronellol. As a means of improving metabolic 
flux in this system, we also experimented with the use of protein scaffolds to co-localize 
vulnerable pathway enzymes together. We demonstrate that protein scaffolds successfully 
bind their targets in vivo, and as a test case showed we could raise the production of 
citronellol up to 57.8%. These discoveries have serious implications for the 
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1. INTRODUCTION  
 
1.1 The Monoterpenoid Indole Alkaloids   
 
The monoterpene indole alkaloids (MIAs) are a large and chemically diverse class of 
naturally occurring plant metabolites. They are defined by a common chemical core, 
which consists of a terpene component containing the glycolsated Iridiod secologanin and 
an indole component comprising tryptamine (Figure 2). This natural scaffold gives rise to 
over 3000 different molecules that are produced by thousands of plant species [1].  
Scientific interest in the MIA’s is primarily due to their wide-ranging and potent 
pharmacological effects.  Well known examples include the antimalarial quinine, rat 
poison strychnine, and anti-hypertensive reserpine. In addition to these, over a dozen 
other MIA’s have been identified as having important biological activities (Table 1).  The 
most significant and well-known MIA’s however have been the anti-cancer drugs 
vinblastine (VBL) and vincristine (VCR). First isolated in 1958 by the Canadian chemists 
Robert Noble and Charles Beer from the leaves of Catharanthus Roseus, these drugs 
were found to be potent inhibitors of microtubule formation and were the first natural 
products used to treat cancer [2]. The discovery provided a scientific explanation for the 
medicinal properties of C. roseus, which had a long history of medical folklore. 
Vinblastine and vincristine have since been proven to be effective treatments for 
Hodgkin’s lymphoma, lung cancer, bladder cancer, brain cancer, testicular cancer and 
many others diseases [3–5]  Both molecules are listed on the WHO’s list of modern 
essential medicines [6], and are considered a key part of a modern health care system.  
For this reason, the production of MIA’s such as VBL and VBC is an area of great 





Table 1: List of pharmaceutically active MIA's and their functions 
Alkaloid Known For  Plant source Reference 




Ajmalicine  Anti-hypertensive  
C.roseus, R.serpentina 
[7] 
Alstonine  Anti-psychotic  





Ellipticine  Anti-Cancer 




Emetine Anti-protozoal,  
emetic  
C. ipecacuanha, P. 
ipecacuanhau 
[11] 
Quinidine Anti-arrhythmic agent 
C. ledgeriana 
[12] 
Quinine Anti-malarial  C. ledgeriana [13] 
Rescinnamine Anti-hypertensive  R. serpentina [14] 
Reserpine  Anti-psychotic, anti-
hypertensive 
R. serpentina [15] 
Toxiferine  Muscle relaxant  S. toxifera [16] 
Vincamine  Vasodilator  
V. minor 
[17] 







1.2 Production Strategies and Economics of the Monoterpenoid Indole Alkaloids   
  
Current production processes for VBC, VBL and most other MIA’s rely almost entirely 
on the mass cultivation of C. roseus. After the plant has reached maturity, the leaves are 
mechanically harvested, pooled and prepared for extraction. Several extraction methods 
have been explored including centrifugal partition chromatography, supercritical CO2 
extraction [19], negative pressure cavitation [20] and ultrasound assisted extraction [21]. 
The central problem with C. roseus-based alkaloid production is that in planta levels of 
dimeric bis-indole alkaloids are extremely low, usually in the range of 0.01-0.1 
mg/gDCW [22]. At these concentrations, a single gram of vinblastine requires over 
500kg of C. roseus leaves to produce [23], and costs anywhere from 770-3170$/g [24].  
The overall process is costly, inefficient, and extremely laborious.  The low yield and 
high production cost of these drugs is a major constraint on their use worldwide, and is a 
problem that needs to be urgently addressed. This demand has spurred research into 
alternate production strategies including direct chemical synthesis, in vitro cell culturing, 
and metabolic engineering of C. roseus. The next section of this thesis will review the 
progress of these methods with respect to VBL and VBC production. Although 
impressive technical advances have been made in all three areas, none have found 
significant use as a large-scale MIA production platform.  
 
1.2.1 Chemical Synthesis of MIA’s   
 
Chemical synthesis of VBL and VCR could provide an ideal solution to production 
problems inherent in C. roseus as it side-steps the use of plant biomass. A major technical 
challenge to this approach however is in the high entantio-structural complexity of the 
dimeric bis-indole alkaloids (Figure 1).  There are 7 chiral centers on vinblastine and 9 
chiral centers on vincristine, and any synthetic approach must be careful to maintain this 
chirality.  The general method underlying most chemical synthesis strategies is to couple 
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monomeric MIA’s together, and then functionalize the resulting products. In the case of 
vinblastine, vindoline and catharanthine are coupled to produce anhdrovinblastine, which 
is then oxidized to give vinblastine with an overall yield of 40% [25,26] The reaction is 
not perfectly stereospecific and there is a 20% loss to leurosidine, a vinblastine 
regioisomer [26].  In the case of vincristine there is a slight variation, and a modified 
version of vindoline (N-desmethylvindoline) used in its place to produce N-
desmethylvinblastine. This product is then formylated to vincristine with a 39% overall 
yield [25].  While these methods are efficient, they face the major limitation that they rely 
on monomeric MIA’s such as vindoline and catharanthine as precursors.  These 
molecules are also exceptionally complex, and are currently only produced using C. 
roseus. While they are found in higher quantities than the dimeric bis-indole alkaloids  
(2.08 ± 113 mg/g DW for vindoline and 2.90 ± 384 mg/g DW for catharanthine)[27], 
their availability is still limited by plant production. Although chemical synthesis might 
provide added value for monomeric MIA’s extracted alongside VCR and VBL, the 








1.2.2 Metabolic Engineering of C. roseus  
 
Another potential way to improve MIA production is by metabolic engineering C. roseus 
directly. This strategy has the advantage of working in a system already validated for 
MIA production and even minor improvements in VBL or VBC yields can greatly 
improve the process economics. C. roseus has been proven to be tractable using 
techniques such as A. tumefaciens mediated gene transfer [28] and particle bombardment 
[29].  When the gene deacetylvindoline-4-O-acetyltransferase was transformed to C. 
roseus an increase in vindoline was observed from 1.15 mg/g in the wild type to 1.42-
2.7mg/g in the engineered plants [30]. Another group successfully overexpressed both the 
MIA transcription factor ORCA3 and the geraniol-10 hydroxylase gene [31]. This 
increased the levels of a number of important metabolites such as vindoline (1.25-3 mg/g 
vs 0.7 mg/g in control lines) and catharanthine, (3.65-5.7 mg/g vs. 1.99 mg/g in control 
lines). Levels of the dimeric MIA’s were relatively unchanged however with 0.07mg/g 
vinblastine for the engineered plants vs. 0.05 m/g in the control. While promising in 
theory, attempts to genetically manipulate C. roseus have generally failed to improve 
levels of dimeric bis-indole alkaloids such as VBL and VBC. The complexity of the 
pathway, alongside the complex spatial and environmental regulation of MIA’s in vivo 
makes it difficult to determine what the appropriate metabolic engineering strategy 
should be. Furthermore, the process is hampered by the long growth times and clumsy 
transformation techniques inherent in working with C. roseus. In some cases, transgenic 
C. roseus lines have been reported to be unstable, with the wildtype phenotype re-
emerging after successive generations [32]. These difficulties generally make the idea of 







2.2.3 In vitro Cell Cultures for MIA Production 
 
Growing cultures of C.roseus in bioreactors is another potential way of improving the 
MIA production process. Plant cell cultures have quicker development times, less 
variation in product yield and quantity, and are easier to apply good manufacturing 
practices (GMP) to than whole plant based processes [33]. While this method is generally 
more capital intensive than plant production [34], several strategies can be employed to 
boost MIA yields within cell cultures. These include screening of high MIA producing 
cultivars, optimization of media and culture conditions and employing different feeding 
and elicitation techniques. In many cases this approach has been highly successful. 
Suspension cultures have achieved up to 200 mg/L of adjmaline and 155 mg/L of 
catharanthine which corresponds to a 40 and 31 fold improvement vs. the plant 
respectively [35].  One major drawback to this method is that it is difficult to produce 
more complex MIA’s such as the dimeric bis-indole alkaloids VBC and VBL. This is 
because their biosynthesis is a highly coordinated process in planta, and involves 
multiple cell types. While VCR and VBL ultimately accumulate in the epidermal latificer 
cells, the pathway spans at least four different cell types and much of the specifics behind 
the spatial organization is unknown [36]. This makes it difficult to produce dimeric bis-
indole alkaloids unless co-cultures or precursor feedings are employed.  
 
2.2.4 Summary of Production Systems for the Monoterpene Indole Alkaloid’s  
 
Production of MIA’s using C. roseus is an expensive and inefficient process and 
alternative approaches have so far been unable to solve this problem. C. roseus is too 
complex and slow growing to engineer efficiently, and transgenic cultivars can be 
genetically unstable. VBC and VBL can be synthesized chemically, but these procedures 
are ultimately dependent on monomeric MIA’s, which themselves must be extracted from 
C. roseus. In vitro plant cultures can provide sources for monomeric MIA’s, but the 
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distribution of the pathway across multiple cell types makes the production of compounds 
like VBL and VCR difficult. A logical solution to this problem would be to reconstruct 
this pathway in a more tractable host such as Saccharomyces cerevisiae.  Genetically 
modified yeast would provide an efficient, scalable, cost effective way of producing 
critical MIA’s. Furthermore, an MIA-producing platform S. cerevisiae strain could be 
customized to facilitate exploration of a large alkaloid structural space, which could 
potentially lead to the discovery of new pharmaceuticals. Yeast already has a successful 
track record in this area, being used to produce valuable natural product-sourced 
pharmaceuticals such as the anti-malarial artemisinin [37] and more recently the 
benzylisoquinoline alkaloids [38–40]  
 
2.3 MIA Biosynthesis and Pathway  
 
2.3.1 Overview  
 
The MIA pathway is highly complex and poorly understood.  While there are parts of the 
pathway that are well characterized, such as biosynthesis of geraniol, tryptamine, as well 
as early Iridiod biosynthesis, there are large gaps in our knowledge of the enzymatic 
synthesis of even basic MIA monomers such as vindoline and catharanthine. While there 
are still many things that remain unknown about the MIA biosynthetic pathway, the field 
has advanced enough to allow for significant groundwork to be done in reconstructing the 
pathway in yeast. The discovery of several genes the in the early Iridiod pathway have 
opened the possibility of creating strictosidine producing strains of yeast de novo [22, 41, 
42, 43] . As strictosidine is the universal precursor for all MIA’s, this would be extremely 
valuable. The next section of this work will review the biochemistry of the pathway as it 
relates to potential for strain engineering. For simplicity, it can be divided into four parts: 
1) the shikimate pathway, producing the indole subunit tryptamine, 2) the mevalonate 
pathway producing the terpene geranyl pyrophosphate, 3) the “early” MIA pathway 
covering up the biosynthesis of strictosidine and, 4) the late MIA pathway covering the 
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steps from strictosidine to VBL/VBC.  
 
 
Figure 2: Overview of the MIA Pathway. The general pathway can be divided into four 
parts: 1) The shikimate pathway leading to the biosynthesis of tryptamine. 2) The 
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mevalonate pathway from acetyl-coA to geranyl-pyrophosphate. 3) The “early” MIA 
pathway from geraniol to the universal MIA precursor strictosidine. 4) The “late” MIA 
pathway from strictosidine to VBL and VCR. Abbreviations: GES, geraniol synthase; 
TDC, tryptophan decarboxylase; STR, strictosidine synthase; PRX1, peroxidase 1. 
 
2.3.2 The Shikimate Pathway 
 
The shikimate and mevalonate pathways provide the respective terpene and indole 
portions of MIA pathway, and are the starting points of the biosynthetic process.  The 
shikimate pathway is common to bacteria, fungi and algae is required to produce the 
aromatic amino acids phenylalanine, tyrosine and tryptophan [44]. It begins using the 
glycolytic products PEP and E4P, which condense to DAHP through DAHP synthase. 
From here, a series of 6 additional enzymatic reactions are needed to produce chorismate, 
which is the common precursor to the aromatic products of this pathway.  Chorosimate 
can be converted to anthranilate by anthranilate synthase, which is then ribosylated by 
phosphoribosyl diphosphate PR-anthranilate transferase.  This molecule is then 
isomerized by PR-anthranilate isomerase to create 1-(O-carboxyphenylamino)-1-
deoxyribulose phosphate. Partial cyclization by indole-3-glycerol phosphate synthase 
yields indole-3-glycerol phosphate.  The two enzymes tryptophan synthase ∝  and 𝛽 
synthase act on this molecule to form tryptophan through an indole intermediate.  The 
last step to create tryptamine is the expression of a tryptophan decarboxylase (TDC), 
which is not native to yeast but has been well characterized in C. roseus [45]. As yeast is 
a native tryptophan producer no genetic modifications other than the expression of TDC 
are needed to form the indole precursor tryptamine.  
 
2.3.3 The Mevalonate Pathway 
 
The biosynthesis of GPP proceeds by the mevalonate pathway (Figure 3), which is 
common to all eukaryotes, archae and some bacteria [46]. This pathway is essential to 
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yeast cellular viability and is responsible for the production of important sterols and 
polyisoprenoids such as squalene and ergosterol. It begins with the condensation of two 
acetyl-CoA’s by the enzyme acetyl-CoA thiolase to form aceto-acetyl-CoA. An 
additional acetyl-CoA is added by acetyl-coA acetyltransferase (ERG10) to create 3-
hydroxymethylglutaryl-CoA (HMG-CoA). This molecule is toxic, and is an important 
natural bottleneck in the pathway [47]. A reduction of HMG-CoA by the enzyme 
hydroxymethylglutaryl-coA synthase (ERG13) gives mevalonate, which undergoes a 
series of phosphorylations, first by mevalonate kinase  (ERG12), then by 
phosphomevalonate kinase (ERG8) to form mevalonate pyrophosphate. This can then be 
decarboxylated by mevalonate decarboxylase (Mvd1) to create isopentyl pyrophosphate. 
IPP is the basic building block for all terpinoids and can be isomerized to 
dimethylallyphosphate (DMAPP) by IPP isomerase (IDI).  As a final step in monoterpene 
biosynthesis, DMAPP and IPP condense to form GPP by the action of farnesyl 
pyrophosphate synthase (ERG20).  This enzyme can also catalyze an additional reaction 
of GPP with DMAPP to create the base sesquiterpene farnesyl-pyrophosphate (FPP). The 
pathway is regulated at the molecular level, and the pyrophosphates GPP and FPP both 
cause feedback inhibition to mevalonate kinase, which can lead to elevated levels of 
intracellular mevalonate [48].  While the MIA monoterpene precursor GPP is naturally 
produced by yeast, it is quickly converted to FPP and most strains of yeast do not 
produce monoterpenes [49]. Therefore, the first step in producing MIA’s in yeast should 





Figure 3: The mevalonate pathway from S. cerevisiae. Abbreviations: ERG10, 
acetoacetyl-coA thiolase; ERG13, 3-hydroxy-3-methylglutaryl-CoA synthase; tHMGr, 3-
hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase; ERG12, mevalonate kinase; 
ERG 8, phosphomevalonate kinase; MVD1; mevalonate decarboxylase; IDI, isopentyl 








Genetically modifying yeast to produce monoterpenes has been explored previously and 
has a wide range of applications from improving the organoleptic properties of white 
wines [49] to producing biofuels [50]. This can be achieved by overexpressing enzymes 
of the mevalonate pathway[37,51]  and by introducing variants of the native yeast ERG20 
enzyme that impairs its ability to bind GPP and convert it to FPP [52]. FPP is an essential 
metabolite that leads to sterol synthesis in yeast but is an undesirable product when 
optimizing GPP synthesis. Alternatively, there are plant analogs of Erg20 such as the 
Gpps2 enzyme from Abies grandis that produce GPP exclusively [53]. Other methods 
focus on increasing the global terpene supply such as overexpressing the tRNA regulator 
MAF1 to reduce loss of IPP to tRNA [54]. Additionally, the mutant transcription factor 
UPC2-1 can be expressed to globally up regulate the genes involved in sterol 
biosynthesis [55]. By using these methods, it has been demonstrated that yeast is capable 
of making a wide range of monoterpenoids such as linalool (95 μg/L) [56], geraniol 
(36.04 mg/L)  [57],  limonene  (0.49 mg/L) [58] at high titers.  
 
 
2.3.4 The MIA Pathway to Strictosidine   
 
The “early” pathway begins at geraniol and extends to the universal MIA precursor 
strictosidine (Figure 4).  The process starts with the hydroxylation of geraniol by the 
cytochrome P450 G10H and it’s associated reductase CPR [59].  After hydroxylation, 10-
hydroxygeraniol undergoes two successive oxidations by the enzyme 10-hydroxygeraniol 
oxidase (10HGO) to form 10-oxogeraniol [60]. This is then cyclized by the reductive 
cyclase Iridiod synthase (IS) to form nepetalactol, which exists in chemical equilibrium 
with the dialdehyde iridodial. Nepetalactol is further oxidized by the enzyme 7-
deoxyloganic acid synthase (7DLS) to form 7-deoxyloganetic acid. This is glycolsated by 
7-dexoxyloganetic acid glucosyl transferase (7DGLT), hydroxylated by 7-deoxyloganic 
acid hydroxylase (7DLH) and methylated by loganic acid O-methyltransferase (LAMT) 
to form loganin. Finally, the cyclopentane ring in loganin is cleaved by the enzyme 
secologanin synthase (SLS) to form secologanin, which condenses with L-trypatime via 
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Figure 4: The “early” MIA pathway from GPP to strictosidine. From the mevalonate 
pathway intermediate GPP, a total of eleven genes are necessary to reach strictosidine. 
Abbreviations: GES, geraniol synthase; G10H, geraniol 10-hydroxylase; CPR, 
cytochrome P450 reductase; 10HGO, 10-hydroxygeraniol oxidoreductase; IS, Iridiod 
synthase; 7DLS, 7-deoxyloganic acid synthase; DLGT, 7-dexoxyloganetic acid glucosyl 
transferase; 7DLH, 7-deoxyloganic acid hydroxylase; LAMT, loganic acid O-
methyltransferase; SLS, secologanin synthase; STR, strictosidine synthase; ADH2, 





2.3.5 The MIA Pathway to Vinblastine/Vincristine   
 
The reactions after strictosidine, referred to here as the “late MIA pathway” are 
ultimately responsible for creating commercially valuable MIA’s such as VBL, VBC and 
adjmaline (Figure 5). A major limitation in reconstructing the entire MIA pathway in 
yeast is that many steps in this pathway remain unknown, or are entirely hypothetical.  
This section will review the parts that are known, and how they relate to the goal of 
biosynthesizing high value MIA’s in S.cerevisiae. The first step in the synthesis of VBL 
or VBC is the deglycolysation of strictosidine to create cathenamine by the enzyme 
strictosidine beta-glucosidase [46].  A cathenamine reductase can then be used to form 
the anti-arrhythmic adjmaline, which the most easily accessible MIA that is commercially 
valuable. Cathenamine also exists in chemical equilibrium with 4,21-
dehydrogroissoschizine, and this is thought to continue down the pathway to form 
stemmadeniene [62], although the exact enzymatic process is unknown. Stemmadeniene, 
when fed to C. roseus suspensions cultures, produces the important MIA’s catharanthine 
and tabernosine [63], though again the exact steps are unknown. The pathway is better 
understood after this point and tabernosine undergoes conversion to vindoline through a 
series of 8 enzymatic reactions [64]. This section of the pathway was recently 
reconstructed in yeast and the resulting strains were able to convert fed tabernosine to 
vindoline with a 7.5% efficiency [64].  Vindoline and catharanthine are then coupled 
together by a peroxidase to form the highly unstable dihydropyroiminium, which 
spontaneously rearranges to ∝-3’,4-anhydrovinblastine [65].  Finally, this molecule can 
be hydroxylated across the double bond to form vinblastine or the N-methyl groups can 
be oxidized to yield vinblastine. 
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Figure 5: The MIA pathway from strictosidine to Vinblastine/Vincristine.  
Abbreviations: SDG, strictosidine beta-D-glucosidase; CR, cathenamine reductase; T30, 
tabernosine 3-oxygenase; T3R, tabernosine 3 reductase; T16H, tabernosine 16 
hydroxylase; 16OMT, 16-hydroxytabersonine O-methyltransferase; NMT, 3-hydroxy-16-
methoxy-2,3-dihydrotabersonine N-methyltransferase; D4H, desacetoxyvindoline-4- 
hydroxylase; DAT, deacetylvindoline-4-O-acetyltransferase  
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2.4 General Reconstruction Strategy  
 
While VBR and VBL are ultimately the most valuable MIA’s, they make poor initial 
synthesis targets due both to their complexity and the lack of information surrounding the 
intermediate enzymatic processes. Strictosidine is a more logical initial goal as all the 
enzymes required for its formation have been discovered and it is the common MIA 
precursor. By integrating all of the enzymes in the early MIA pathway in a GPP 
overproducing strain, strictosidine biosynthesis was recently achieved in yeast at low 
yields [66]. Although this is in important technical advancement, higher titers will be 
needed to reach downstream products like VBL and VBC, which are 21-23 additional 
enzymatic steps from strictosidine. In this thesis we report on the engineering of a 
nepetalactol-producing yeast strain as a first step to optimizing strictosidine biosynthesis 
in S. cerevisiae. The work was done in a two-stage process (Figure 6). First we optimized 
production of the base monoterpene geraniol using a combination of MVP enzyme 
overexpression and integration of an ERG20K197E mutation. Next, we characterized the 
downstream enzymes to nepetalactol and showed 10-hydroxygeraniol production in vivo 
as well as nepetalactol production in vitro. We also demonstrate that activity of the 
Iridiod synthase towards the intermediates geraniol and 10-hydroxygeraniol results in the 
synthesis of the non-productive intermediates citronellol and 10-hydroxycitronellol. This 








Figure 6: Metabolic engineering strategy to achieving nepetalactol synthesis in 
S.cerevisiae. Overexpressed yeast endogenous mevalonate pathway genes (blue) and 
plant genes (red) leading to nepetalactol. The endogenous ScERG20 gene was replaced 
with Sc.erg20K197E to decrease flux to FPP and improve GPP synthesis. Abbreviations: 
ScERG13, S. cerevisiae 3-hydroxy-3-methylglutaryl-CoA synthase; SctHMGR, S. 
cerevisiae 3-hydroxy-3-methylglutaryl-CoA reductase; Sc.ERG12, S. cerevisiae 
mevalonate kinase; ScERG8, S. cerevisiae phosphomevalonate kinase; ScMVD1 S. 
cerevisiae mevalonate pyrophosphate decarboxylase; ScIDI1, S. cerevisiae isopentenyl 
pyrophosphate synthase; Sc.erg20K197E, S. cerevisiae farnesyl pyrophosphate synthase 
variant; Ag.gpps, Abies grandis geranyl pyrophosphate synthase; ObGES, Ocimum 
basilicum geraniol synthase; CrG10H, C. roseus geraniol 10-hydroxylase; C. roseus 
cytochrome P450 reductase; Cr10HGO, C. roseus 10-hydroxygeraniol oxidoreductase; 
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CrIS, C. roseus Iridiod synthase; ScLIS, S. cerevisiae linalool synthase (hypothesized, not 
yet identified), ScOYE2/3, S. cerevisiae NADPH dehydrogenase. Metabolites: IPP, 
isopentenyl pyrophosphate; DMAPP, dimethylallyl pyrophosphate; GPP, geranyl 
pyrophosphate; FPP, farnesyl pyrophosphate. 
 
2.5 Synthetic protein scaffolds     
 
The promiscuous activity of IS on geraniol was found to be a major barrier to 
reconstituting the MIA pathway in yeast.  One potential way to fix this problem would be 
to use synthetic enzyme co-localization to physically sequester IS from the upstream 
enzymes. This can done using synthetic protein scaffolds, which can be highly effective 
at directing metabolic flux and improving overall pathway efficiency [67,68] . The basic 
structure of a protein scaffold is a set of modular protein binding domains strung together 
by flexible serine glycine linkers of the format (GGSG)x (Figure 7). Peptides 
complementary to the binding domains are fused to enzymes in the desired pathway, 
which are then recruited to the scaffold.  The domains used should be small, simple and 
have specific, tight binding ligands. Furthermore, they should not be dependent on ions, 
cofactors or post-translational modifications for function.  Through a literature review, 
we have determined that the SH3 [69], GBD [70], SYNZIP1/2 [71], SYNZIP3/4 [71] and 
WW [72] domains would be appropriate candidates for a yeast scaffolding project. We 
have taken preliminary steps to characterizing the binding functionality of these domains 
in vivo. We also show that protein scaffolds can be used to improve metabolic flux within 
the MIA pathway.  This makes them a useful tool for dealing with enzymatic spatial and 
regulatory problems that can occur when engineering long metabolic pathways in non-




Figure 7: General structure of a synthetic protein scaffold: Scaffolds are created by 
fusing modular protein binding domains together by flexible glycine-serine linkers.  
Pathway enzymes are fused to peptides ligands containing binding the complementary 
domains, which are co-localized together on the scaffold.  Adapted from [73].   
 
MATERIALS AND METHODS 
3.1 Strains and plasmids   
 
Strains of S. cerevisiae used in this study and their genotype are listed in Table 2. 
Escherichia coli DH5α was used to maintain and propagate plasmids. Escherichia coli 
was grown at 37°C and 200 rpm in LB medium supplemented with 100 µg/mL of 
ampicillin. S. cerevisiae was grown at 30°C and 150 rpm in either the rich medium YPD 
or the defined SD medium. When required, 200 µg/mL geneticin was added to YPD and 
SD medium was supplemented with amino acids to complement specific auxotrophic 
requirements. 
 
All plasmids used in this study and the genes, promoters and terminators they contain are 
described in Table 2. Primers used in this study are listed in Table 3 The DNA assembler 
method [74] was used to construct the plasmids. The different DNA parts were amplified 
by PCR using Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific), 
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resolved by gel electrophoresis and individually purified using Qiagen Gel Purification 
kit (Valencia, CA, USA). DNA parts (promoter, gene, terminator) with overlapping 
homologous sequences were pooled with a linearized plasmid and transformed into the 
appropriate auxotrophic yeast strain using either the Gietz method[75] or by 
electroporation, as described by Shao et al[76]. Assembled plasmids were selected by 
growth on minimal medium and the resulting plasmids were recovered from yeast and 
transformed into E. coli for maintenance. Sanger sequencing confirmed correct assembly 
of each construct. Promoters and terminators required for assembly were amplified from 
S. cerevisiae CEN.PK gDNA. Yeast mevalonate pathway genes ERG8, ERG12, ERG13 
and a truncated HMGR (tHMGR) were also amplified from S. cerevisiae CEN.PK gDNA 
and assembled together into either the high-copy shuttle vector pYES2 (Thermo 
Scientific) or a centromeric plasmid derived from pGREG505 . Genes originating from 
plant species were assembled into similar versions of the multi-copy pYES(TRP) or 
pYES(URA). Geraniol synthase from Ocimum basilicum (ObGES) was assembled from 
synthesized gBlocks (Integrated DNA Technologies) based on the cDNA sequence 
(GenBank accession AY362553). Geraniol pyrophosphate synthase from Abies grandis 
(AgGPPS2) as well the cytochrome P450 reductase (CrCPR), the geraniol 10-
hydroxylase (CrG10H) and the 10-hydroxygeraniol oxidoreductase (Cr10HGO) from C. 
roseus were codon optimized for expression in S. cerevisiae and synthesized by DNA 2.0 
(GenBank accession to be submitted). The Iridiod synthase gene (GenBank accession 
JX974564) isolated from C. roseus cDNA by V. de Luca (Brock University) and cloned  
using primers 1060F and 1060R (Table 4). 
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Table 2: Strains and plasmids used in this work 
Strain designation Genotype Source  
CEN.PK113-17A MATα; leu2-3,112 ; ura3-52 ; MAL2-8C; SUC2 EUROSCARF 
CEN.PK113-16D MATα; trp1-289 ; MAL2-8C; SUC2 EUROSCARF 
CENPK2-1D MATα;  leu2-3,112 ; ura3-52 ; his3-Δ1;  trp1-289; MAL2-8C; SUC2 EUROSCARF 
CEN.PK113-17A 
ERG20K197E 





MATα; leu2-3,112 ; ura3-52 ; his3Δ 1;  trp1-289; MAL2-8C; SUC2 ; 
erg20Δ::PTPI1-erg20K197E-loxP-kanMX 
This study 
CEN.PK113-14C MATα; leu2-3,112 ; his3Δ 1;  MAL2-8C; SUC2  
   
Plasmid designation Genes and Genotype  Source 
pYES2 2µori, pUC1ori, URA3, bla Thermo Fisher  
pYES2Leu 2µori, pUC1ori, LEU2, bla 49 
pYES2Trp 2µori, pUC1ori, TRP1, bla This study 
pGREG503 CEN6/ARS4ori, pMB1ori, HIS3, bla, loxP-kanMX, PGAL1-YeGFP-TCYC1 Modified from 
47 
pGREG504 CEN6/ARS4ori, pMB1ori, TRP1, bla, loxP-kanMX, PGAL1-YeGFP-TCYC1 Modified from 
47 
pGREG505 CEN6/ARS4ori, pMB1ori, LEU2, bla, loxP-kanMX, PGAL1-YeGFP-TCYC1 Modified from 
47 
pMevH 2µori, LEU2, PFBA1-ScERG8-TCYC1-PTPI-ScERG12-TADH1-PPYK1-ScERG13-TPGI1-
PPDC1-SctHMGR-TADH2 
This study 
pMevL pGREG505, PFBA1-ScERG8- TCYC1-PTPI-ScERG12- TADH1-PPYK1-ScERG13- This study 
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TPGI1-PPDC1-SctHMGR-TADH2 
pGer 2µori, URA3, PPYK1-AgGPPS2-TENO2 -PPDC1-CrCPR-TADH2-PTEF2-ObGES-TTDH2 This study 
pGerOH 2µori, URA3, PPYK1-AgGPPS2-TENO2 -PPDC1-CrCPR-TADH2-PTEF2-ObGES-TTDH2 -
PFBA1-CrG10H-TPGI1 
This study 
pHGO 2µori, TRP1, PTEF1-Cr10HGO-TPGI1 This study 
pHGOIS 2µori, TRP1, PTEF1-Cr10HGO-TPGI1-PTDH3-CrIS-TADH2 This study 
pIS pGREG504, PTDH3-CrIS-TADH2 This study 
pNV-SH3 pGREG503 PTDH3-NV-SH3-TADH2 This study 
pCV-SH3lig pGREG505 PTef1p-CV-SH3lig-TENO2 This study 
pNV-GBG pGREG503 PTDH3-NV-SH3-TADH2 This study 
pCV-GBBlig pGREG505 PTef1p-CV-GBDlig-TENO2 This study 
pNV-SYN1 pGREG503 PTDH3-NV-SYN1-TADH2 This study 
pCV-SYN2 pGREG505 PTef1p-CV-SYN2-TENO2 This study 
pNV-SYN3 pGREG503 PTDH3-NV-SYN3-TADH2 This study 
pCV-SYN4 pGREG505 PTef1p-CV-SYN4-TENO2 This study 
pNV-GHF pGREG503 PTDH3-NV-GHF-TADH2 This study 
pCV-GHFiig pGREG505 PTef1p-CV-GHFlig-TENO2 This study 
pNV pGREG503 PTDH3-NV-TADH2 This study 
pCV pGREG505 PTef1p-CV-TENO2 This study  
pVenus  pGREG503 PTDH3-Venus-TADH2 This study 
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pERGGES pGREG504 PTDH3-ERG20K197E-SYN4 -TENO2- PTef1-GES-GBGlig- TPGI This study 
pOYE2 pGREG506 PTPI-OYE2-SH3lig-Tcyc This study 
pSYN3-(GBD)1-SH3 pGREG503 PTDH3p- SYN3-(GBD)1-SH3-TENO2 This study  
pSYN3-(GBD)2-SH3 pGREG503 PTDH3p- SYN3-(GBD)2-SH3-TENO2 This study 
pSYN3-(GBD)3-SH3 pGREG503 PTDH3p- SYN3-(GBD)3-SH3-TENO2 This study 
 
Table 3: Oligonucleotides used in the work 
Primer name  Sequence 5’-3’  
506 FBA1p F  TAACCCTCACTAAAGGGAACAAAAGCTGGAGCTCGTTTAAACGGCGCGCCATCCAACTGGCACCGCTGGCTTG  
pYES FBA1pF  CGCTACAGGGCGCGTGGGGATGATCCACTAGTATCCAACTGGCACCGCTGGC  
ERG8 FBA1p R  CACTGAAGGCTCTCAACTCTGACATTGTTTTTATGTATTACTTGGTTATGGTTA  
FBA1p ERG8 F  TATAACCATAACCAAGTAATACATAAAAACAATGTCAGAGTTGAGAGCCTTCAGTGC  
CYC1t ERG8 R  AAGCGTGACATAACTAATTACATGATTATTTATCAAGATAAGTTTCCGGATC  
ERG8 CYC1t F  AAGATCCGGAAACTTATCTTGATAAATAATCATGTAATTAGTTATGTCACGC  
TPIp CYC1t R  TATCCGTAATCTTTAAACAGCTAGTGCAAATTAAAGCCTTCGAGCGTCCC  
CYC1t TPIp F  TTTTGGGACGCTCGAAGGCTTTAATTTGCACTAGCTGTTTAAAGATTACGGA  
ERG12 TPIp R  CGGTGCAGAAGTTAAGAACGGTAATGACATTGTTTTTTTATGTATGTGTTTTTTGTAGTTATAGATTTAAGC  
TPIp ERG12 F2  TCTATAACTACAAAAAACACATACATAAAAAAACAATGTCATTACCGTTCTTAACTTCTG  
ADH1t ERG12 R  CTTGACCAAACCTCTGGCGAAGAAGTCCATTATGAAGTCCATGGTAAATTCGTGTTTCC  
ERG12 ADH1t F  CACGAATTTACCATGGACTTCATAATGGACTTCTTCGCCAGAGGTTTGGTC  
PYK1p ADH1t R  GAGATTAATCTCCAAAATAGTAGCATTGCATGCCGGTAGAGGTGTGGTCAAT  
ADH1t PYK1p F  CGCTCTTATTGACCACACCTCTACCGGCATGCAATGCTACTATTTTGGAGATT  
ERG13 PYK1p R  GTTTAGTTGAGAGTTTCATTGTTTTGATGTTTTATTTGTTTTGATTGGTGTC  
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PYK1p ERG13 F  AAAACAAATAAAACATCAAAACAATGAAACTCTCAACTAAACTTTGTTGGTG  
PGIt ERG13 R  CTTTAGGTATATATTTAAGAGCGATTTGTTTTATTTTTTAACATCGTAAGATC  
ERG13 PGIt F  AGAAGATCTTACGATGTTAAAAAATAAAACAAATCGCTCTTAAATATATACC  
PDC1p PGIt R  GCGGAACATATGCTCACCCAGTCGCATGTGGTATACTGGAGGCTTCATGAGT  
PGIt PDC1p F  GGACATAACTCATGAAGCCTCCAGTATACCACATGCGACTGGGTGAGCATAT  
tHMGR PDC1p R  TTTATTGGTTAAAACCATTGTTTTTGATTTGACTGTGTTATTTTGCGTGAGG  
PDC1p tHMGR F  AAATAACACAGTCAAATCAAAAACAATGGTTTTAACCAATAAAACAGTCATT  
ADH2t tHMGR R  AATCGTAAAGACATAAGAGATCCGCTTAGGATTTAATGCAGGTGACGGACC  
tHMGR ADH2t F  GGTCCGTCACCTGCATTAAATCCTAAGCGGATCTCTTATGTCTTTACGAT  
506 ADH2t R  ATAACTTCGTATAATGTATGCTATACGAAGTTATTAGGTACCGCGGCCGCTAGAATTATATAACTTGATGAGATGAG   
pYES ADH2tR  CGCGCGTTGGCCGATTCATTAATGCAGGGCCTAGAATTATATAACTTGATGAG  
pYES PYK1p F2  ACAGGGCGCGTGGGGATGATCCACTAGTAATGCTACTATTTTGGAGATTAA  
GPPS2 PYK1p R  CCCATAGTAGCCATAGCAGAGTAAGCCATTGTTTTGATGTTTTATTTGTTTTGATTGGTG  
PYK1p GPPS2 F  CAAGACACCAATCAAAACAAATAAAACATCAAAACAATGGCTTACTCTGCTATGGCTACT  
ENO2t GPPS2 R  AAAGACTAATAATTCTTAGTTAAAAGCACTTTAGTTTTGTCTGAATGCGACATAGTC  
GPPS2 ENO2t F  GCTGACTATGTCGCATTCAGACAAAACTAAAGTGCTTTTAACTAAGAATTATTAG  
TEF2p ENO2t R  CTATATGTAAGTATACGGCCCCATATAAGGTATCATCTCCATCTCCCAT  
ENO2t TEF2p F  ATATGCATATGGGAGATGGAGATGATACCTTATATGGGGCCGTATACTTACATATAG  
GES TEF2p R  AACTTTCTGGCTTATGGATGACATTGTTTTTTAATTATAGTTCGTTGACCGTATATTCTAA  
TEF2p GES F  TAGAATATACGGTCAACGAACTATAATTAAAAAACAATGTCATCCATAAGCCAGAAAGTT  
TDH2t GES R  CTAAATCATTAAAGTAACTTAAGGAGTTAAATTTAAACGTAAGGTTCGAACATCAACCCGCC  
GES TDH2t F  GGGTTGATGTTCGAACCTTACGTTTAAATTTAACTCCTTAAGTTACTTTAATGATTTAG  
PDC1p ENO2t R  GCGGAACATATGCTCACCCAGTCGCATGTAGGTATCATCTCCATCTCCCAT  
ENO2t PDC1pF  ATATGCATATGGGAGATGGAGATGATACCTACATGCGACTGGGTGAGCATAT  
FBA1p TDH2t R  GTTGTTCAAGCCAGCGGTGCCAGTTGGATGCGAAAAGCCAATTAGTGTGATAC  
TDH2t FBA1p F  AAAGCACTTAGTATCACACTAATTGGCTTTTCGCATCCAACTGGCACCGCTGGC  
G10H FBA1p R  GTCAATATGATAGTTAAGTAATCCATTGTTTTTATGTATTACTTGGTTATGG  
FBA1p G10H F  CATATATAACCATAACCAAGTAATACATAAAAACAATGGATTACTTAACTATCATATTGAC  
PGIt G10H R  GCTTTAATGTTCTTTAGGTATATATTTAAGAGCGATTTGTTTCACAGGGTAGAAGGCACAGCTC  
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G10H PGIt F  CCTTTAAGAGCTGTGCCTTCTACCCTGTGAAACAAATCGCTCTTAAATATATACC  
CPR PDC1p R  GGATAGTTTTTCTGAAGATGAGTCCATTGTTTTTGATTTGACTGTGTTATTTTGC  
PDC1p CPR F  GCAAAATAACACAGTCAAATCAAAAACAATGGACTCATCTTCAGAAAAACTATCC  
ADH2t CPR R  CGTAAAGACATAAGAGATCCGCCTACCAAACATCCCTTAAGTAACG  
CPR ADH2t F  CGTTACTTAAGGGATGTTTGGTAGGCGGATCTCTTATGTCTTTACG  
ADH2t TEF2p F  TTTACTCATCTCATCTCATCAAGTTATATAATTCTATATATGGGGCCGTATACTTACATA  
10HGO TEF1pR  ATGTTCAACTTCTGGAGACTTGGCCATTGTTTTATTAAAACTTAGATTAGATTGCTATGC  
TEF1p 10HGO F  GAAAGCATAGCAATCTAATCTAAGTTTTAATAAAACAATGGCCAAGTCTCCAGAAGTTG  
PGI1t 10HGO R  GTTCTTTAGGTATATATTTAAGAGCGATTTGTTTTAAGCAGACTTTAAGGTATTAGCG  
10HGO PGI1t F  TAATTGACGTCGCTAATACCTTAAAGTCTGCTTAAAACAAATCGCTCTTAAATATATACC  
pYES TEF1p F  ACAGGGCGCGTGGGGATGATCCACTAGTATAGCTTCAAAATGTTTCTACTCC  
PGI1t TDH3p F  CGAAGGACATAACTCATGAAGCCTCCAGTATACCTCGAGTTTATCATTATCAATACTGCC  
IS TDH3p R  CAGCACCAATGGACCTCTTCCACCACCAACTCATTGTTTTTCGAAACTAAGTTCTTGGTG  
TDH3p IS F  TTAGTTTTAAAACACCAAGAACTTAGTTTCGAAAAACAATGAGTTGGTGGTGGAAGAG  
ADH2t IS R  TGAAAACTATAAATCGTAAAGACATAAGAGATCCGCCTAAGGAATAAACCTATAATCCCT  
IS ADH2t F  TTGATAAGATGAGGGATTATAGGTTTATTCCTTAGGCGGATCTCTTATGTCTTTACG  
pYES PG1t R  CGCGCGTTGGCCGATTCATTAATGCAGGGCCCCGCGGCCGCGGTATACTGGAGGCTTCATGAG  
IS F  AGTTGGTGGTGGAAGAGGT  
IS R  AGGAATAAACCTATAATCCCTCAT  
C6 506 R  TAACCCTCACTAAAGGGAACAAAAGCTGGAGCTCGTTTAAACGGCGCGCCGAGACTGCAGCATTACTTTGAGAAG  
C1 506 F  ATAACTTCGTATAATGTATGCTATACGAAGTTATTAGGTACCGCGGCCGCACAACTCATGGTGATGTGATTGCC  
pYES TPIp F  CCTGAATTCTTTTAGTTTATGTATGTG  
pYES CYCt R  ATCATGTAATTAGTTATGTCACGC  
TPIp Erg20 F  TCTTTTCTTGCTTAAATCTATAACTACAAAAAACACATACATAAACTAAAAAAAACAATGGCTTCAGAAAAAGAAATTAG
GAG  
CYCt Erg20 R     GGATGTGGGGGGAGGGCGTGAATGTAAGCGTGACATAACTAATTACATGATCTATTTGCTTCTCTTGTAAACTTTGTTCAA
G  
pYES CYCt R  GGCCCTGCATTAATGAATCGGCCAAC  
pYES F 2nd     GCAAATTAAAGCCTTCGAGCGTCC  
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Kanx CYCt F  ACCTTGCTTGAGAAGGTTTTGGGACGCTCGAAGGCTTTAATTTGCCAGCTGAAGCTTCGTACGCTG  
Kanx pYES R  AAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGGGCCGCATAGGCCACTAGTGGATCTG 
pYES CYC R 2nd GGCCCTGCATTAATGAATCGGCCAAC 
TDH3p NVenus F TTTTTAGTTTTAAAACACCAAGAACTTAGTTTCGATCTAAAGGTGAAGAATTATTCACTG 
TDH3p NVenus R  CAACACCAGTGAATAATTCTTCACCTTTAGACATTGTTTTTCGAAACTAAGTTCTTGGTG  
NVenus Eno2 F AATGTTTACATCACTGCTGACAAACAATAATAGAGTGCTTTTAACTAAGAATTATTAGTC  
NVenus-L1 R caatgtttacatcactgctgacaaacaaGGTGGAGGTTCTGGTGGAGGTAGTGGT 
L1-SH3 F GGTGGAGGTTCTGGTGGAGGTAGTGGTATGGAAGATTTGCCATTCAAGAAGGG 
SH3-L2 R  CTAGTGATGGTGATGATGATGACCACTACCTCCACCAGAACCTCCACCTCCACCAATCAAAGCAGAAACAGAAG 
L2-ADH2t F GAACAAAAGTTGATCTCCGAAGAAGATTTGTAGGCGGATCTCTTATGTCTTTACGATTTA 
L1-SYN1 F GGTGGAGGTTCTGGTGGAGGTAGTGGTAACTTGGTTGCCCAATTGGAAAAC 
SYN1-L2R CTAGTGATGGTGATGATGATGACCACTACCTCCACCAGAACCTCCACCTTCTTCAATCTTCTTTCTTAAGTTGGCGATTT 
 L1-SYN3 F GGTGGAGGTTCTGGTGGAGGTAGTGGTAACGAAGTTACCACCTTGGAAAATGA 
SYN3-L3 R CTAGTGATGGTGATGATGATGACCACTACCTCCACCAGAACCTCCACCTTTCTTATGGGCCAATCTGTTTCTCAA 
L1-GBD F GGTGGAGGTTCTGGTGGAGGTAGTGGTAAGGCCGATATTGGTACTCCATCTAA 
GBD-L2 R CTAGTGATGGTGATGATGATGACCACTACCTCCACCAGAACCTCCACCTGGGGCTTGTCTTCTCAATTCATTC 
L1-GHF GGTGGAGGTTCTGGTGGAGGTAGTGGTGATGTCATGTGGGAATACAAGTGGG 
GHF-L2  CTAGTGATGGTGATGATGATGACCACTACCTCCACCAGAACCTCCACCGGTGTACAAGTCGAAGTCAATTCTCTT 
TEF2p-L1 R ACCACTACCTCCACCAGAACATTGTTTTTTAATTATAGTTCGTTGACCGTATATTCT 
L1-SH3lig F GGTGGAGGTTCTGGTGGAGGTAGTGGTCCACCACCAGCTTTGCCAC 
SH3lig-L3 R CAAATCTTCTTCGGAGATCAACTTTTGTTCACCACTACCTCCACCAGAACCTCCACCTCTTCTTCTTTTTGGTGGCAAAGCTT
AG 
L2-Eno2t F TTCTGGTGGAGGTAGTGGTCATCACCACCATCACCATTAGAGTGCTTTTAACTAAGAATTATTAGTCTTTTC   
L1-SYN2 F GGTGGAGGTTCTGGTGGAGGTAGTGGTATTAACTATTTTACACCAGGCATATAGTGGTTTG 
SYN2-L2 R CTACAAATCTTCTTCGGAGATCAACTTTTGTTCACCACTACCTCCACCAGAACCTCCACCGATCTTTTTTGCATAACGTGCA
TCAAAGC 
L1-SYN4 F  GGTGGAGGTTCTGGTGGAGGTAGTGGTCAAAAGGTTGCCGAATTGAAGAATAGAG 
SYN4-L2 R CTAGTGATGGTGATGATGATGACCACTACCTCCACCAGAACCTCCACCTTCAGCGACATCATTTTCCAATCTGG 




L1-GHFlig F GGTGGAGGTTCTGGTGGAGGTAGTGGTGAATTTGGTCCACCACCAGGTC 
L3-GHFlig R CTACAAATCTTCTTCGGAGATCAACTTTTGTTCACCACTACCTCCACCAGAACCTCCACCCAATCTTTGACCTGGTGGTGGA
C 
NVenus-ADH2t F ctataactctcacaatgtttacatcactgctgacaaacaaTAGGCGGATCTCTTATGTCTTTACGATT 
NVenus-ADH2t R GATAATGAAAACTATAAATCGTAAAGACATAAGAGATCCGCCTAttgtttgtcagcagtgatgtaaacattg 
CVenus-ENO2t F tgctggtattacccatggtatggatgaattgtacaaataaTAGagtgcttttaactaagaattattagtcttttctgc 
CVenus-ENO2t R aataagcagaaaagactaataattcttagttaaaagcactCTAttatttgtacaattcatccataccatgggta 
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3.2 Integration of the erg20K197E mutation  
 
The chromosomal knock-in of the erg20K197E mutation was done by homologous 
recombination using an antibiotic marker-containing disruption cassette created by PCR, 
as described by Rothstein.  erg20K197E was generated by overlap extension PCR to 
introduce the base pair change corresponding to K197E. The mutation was integrated as a 
PTPI1-erg20
K197E-TCYC1-loxP-kanMX-loxP cassette flanked by homology to the ERG20 
chromosomal locus. Our attempts to introduce the K197E mutation into a haploid strain 
failed, possibly due to the combined stress of the transformation process and the 
metabolic burden of the mutation to a single copy of an essential gene. To decouple these 
effects, the cassette was transformed into a diploid strain and transformants were selected 
on YPD supplemented with 200 μg/mL G418. The diploid transformants were sporulated 
and segregated to generate the haploid mutant strain. Stability of the integration was 
verified after several propagations and the erg20K197E locus was PCR amplified and 
sequence verified. This mutation was introduced into both double and quadruple 
auxotrophic yeast in the same manner. 
 
3.3 Analysis of Monoterpenoid Production in S. cerevisiae  
 
To measure monoterpenoid production, strains were seeded in triplicate to an OD600 of 
0.05 in 40 mL of SC medium in 250 mL flasks and incubated at 30°C and 200 rpm over a 
period of 4 days.  For monoterpenoid analysis, 1-mL culture samples were extracted into 
0.25 volumes of ethyl acetate containing 10.7 mg/L of eugenol as internal standard. 
Extracts were analyzed by GC-EI-MS using an Agilent 6890N GC system coupled to an 
Agilent 5875 mass selective detector. Three μL of extracts were injected in pulsed 
splitless mode at 50 PSI for 0.5 min with an injection temperature of 250°C. Hydrogen 
was used as a carrier gas at a constant flow of 1 mL/min. A 10-min temperature gradient 
ranging from 80 to 300°C was used to separate analytes over a DB-5ms column (25 m × 
0.20 mm × 0.33 μm film thickness). Analytes were identified and quantitated using linear 
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calibration curves with authentic standards in concentrations ranging up to 100 mg/L. 
Geraniol concentration was evaluated by scanning for three ions: 93, 123 and 154 m/z. 
Nepetalactol was measured by following ions 135 and 168 m/z. Mevalonate was 
estimated by monitoring only 58 m/z.  Linalool, citronellol, eugenol and 10-
hydroxygeraniol were measured using the Total Ion Chromatogram (TIC) scanning for 
m/z values of 50-220. For lack of authentic standards in the cases of 10-
hydroxycitronellol and 10-hydroxylinalool, concentrations were estimated using the 10-
hydroxygeraniol standard curves. Means are reported and errors are given as confidence 
interval (p<0.05). 
 
3.4 10-Hydroxygeraniol Oxidoreductase and Iridoid Synthase Assays     
 
Yeast cellular extracts were prepared in order to measure 10-hydroxygeraniol 
oxidoreductase and Iridiod synthase activity. To prepare the extracts, overnight cultures 
of the strain expressing CrIS, Cr10HGO, Cr10HGO-CrIS or an empty vector control 
were used to inoculate 100 mL of SC medium to an OD600 of 0.05. After 24 hours of 
growth, cells from triplicate 15-mL volumes of each culture were harvested by 
centrifugation for 5 min at 3200 × g. For the CrIS assays, cells were washed twice with 
900 µL of 150 mM MOPS pH 7 and placed in a 2-mL conical microtube with silicon O-
ring. Approximately 0.1 mL of glass beads were added to each tube and the cells were 
lysed by 3 x 30 seconds long cycles at 6000 rpm in a Precellys homogenizer.  The 
homogenizer was maintained at 4°C with 45 seconds between cycles. Immediately after 
lysis, 100 µL of a stock solution containing 10x protease inhibitor (1 tablet/mL, Complete 
Mini EDTA free, Roche) and 5 mM of both geraniol and NADPH were added to the 
lysates to achieve a final concentration of 500 µM. For Cr10HGO, Cr10HGO-CrIS 
assays, 50 mM Tris pH 9 was used for lysis and 100 µL of a solution containing 5.45 mM 
10-hydroxygeraniol, 10 mM NAD+ and 10x protease inhibitor (Complete Mini, EDTA 
free, Roche) was added to 900 µL the lysates. This gave a final concentration of 545 µM 
10-hydroxygernaiol and 1mM NAD+. Cr10HGO catalyzes two successive oxidations, but 
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at low pH can also act as a reductase and perform the reverse reactions [22]. Therefore, 
assays were run at pH 9 to maximize the oxidative activity of Cr10HGO. All assay 
samples were incubated for 1 hour at 30°C then extracted with ethyl acetate and analyzed 
by GC-EI-MS as described above.    
 
3.4 Split Venus Protein-Protein Interaction Assay  
 
Protein fragments to be tested for interaction were fused 5’ with either the N-terminal 
(amino acids 1-158) or C-terminal (amino acids 159-239) domains of the YFP variant 
Venus. The Venus-domain fusions were cloned into plasmids under the expression of a 
constitution promoter and complementary protein fragments were co-transformed into S. 
cerevisiae. If protein binding is successful, the Venus fragments should reassemble and 
the fluorescent signal will be reconstituted (Figure 8).  Cells containing complementary 
Venus fragments were grown until mid logarithmic phase, where a 100 ul sample was 
collected, washed once in PBS, then re-suspended in 1 ml PBS for analysis. Data was 
collected using a BD AccuriTM C6 flow cytometer. Gates were set around a non-
fluorescent control to standardize for forward (FSC) and side (SSC) light scattering. All 
fluorescence data was collected using an emission laser set at 488nm and a 530/30nm 




Figure 8: Split Venus protein-protein interaction assay. Protein binding partners are fused to the N-
terminal and C-terminal fragments of a Venus fluorescent protein. If the proteins 





4.1 Geraniol synthesis in S. cerevisiae 
 
As a first step towards achieving 10-hydroxygeraniol synthesis in yeast, increased 
metabolic flux to GPP was engineered in a wild-type strain. As GPP is unstable and 
causes feedback inhibition to the upstream gene mevalonate kinase [48], geraniol 
synthesis was used as our read-out. Expression of the O. basilicum geraniol synthase 
(ObGES) [78] was used to convert GPP to geraniol in yeast. Additionally, flux through 
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the mevalonate pathway was increased by the recombinant expression genes ERG13, 
tHMGR, ERG8 and ERG12 (Figure 6). Expression of these four genes was tested from 
either an episomal 2µ (MevH) or a centromeric (MevL) plasmid, and strains were tested 
for geraniol productivity as well as mevalonate to determine the extent of feedback 
inhibition.  
 
 The highest specific production of geraniol observed was from a strain that had the 
mevalonate pathway overexpressed from a low-copy centromeric plasmid, along with the 
erg20K197E chromosomal mutation and the geraniol-producing enzymes AgGPPS2 and 
ObGES (Figure 9). In the erg20K197E background, higher expression of the mevalonate 
pathway did not result in increased concentration of geraniol as compared to low-copy 
expression. In the background of erg20K197E and in the presence of AgGPPS2 and 
ObGES, still low-copy expression of the mevalonate pathway generated more geraniol 
than high-copy expression (Figure 9). This could be due to flux imbalance as the 
mevalonate pathway intermediate HMG-CoA is known to be toxic [47]. In addition, 
mevalonate was found to accumulate to a higher level in the absence of AgGPPS2-
ObGES expression (Figure 7), likely caused by the feedback inhibition of mevalonate 
kinase ScERG12 by GPP/FPP [79] and further supporting the importance of pulling on 
the intracellular GPP pool (Figure 9). Although introducing the erg20K197E mutation 
resulted in improved geraniol production levels, a ~66% decrease in cell density over 
wild-type was observed, which is consistent with previous results [80]. This could be due 
to geraniol toxicity [81] or reduced intracellular FPP pools ultimately limiting ergosterol 
biosynthesis [82].  
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Figure 9: Specific production of the monoterpenoids and mevalonate by engineered 
S.cerevisiae strains. Mevalonate pathway genes ERG8, ERG12, ERG13 and tHMGR 
were overexpressed from a high-copy (pMevH) or low-copy (pMevL) plasmid. The GES, 
GPPS2 and CPR genes were expressed together from a high-copy plasmid (pGer). Wild-
type ERG20 background strain was compared with an erg20K197E mutant strain favoring 
production of GPP over FPP. Asterisks indicate statistically significant (p<0.05) 
improvement in geraniol production, as determined by Student’s paired t-test with two-
tailed distribution. Annotations of *, ** and *** represent statistical differences to the 
control MevH or MevL strains. Error bars represent the 95 % confidence interval from 
triplicate cultures inoculated from a single colony. Note: This experiment was 
performed by Nick Gold and Philippe Bauchart. 
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The production of linalool and citronellol was also measured. Linalool was only observed 
from strains expressing the mevalonate pathway from a low-copy plasmid whereas 
citronellol production followed geraniol, as expected. Based on these results, the 
geraniol-producing strain with the highest yield (pMevL, pGer, erg20K197E) was used as 
the starting strain to further extend the Iridiod pathway.  
 
4.2 10-Hydroxygeraniol Synthesis in S. cerevisiae  
 
Using our highest geraniol-producing strain, we aimed to show activity for the next step 
in the Iridiod pathway, production of 10-hydroxygeraniol. This reaction is catalyzed by 
the cytochrome P450 monooxygenase CrG10H and requires the accessory reductase 
CrCPR [59]. To test the functionality of the monooxygenase in yeast, the genes encoding 
the two enzymes were added to the AgGPPS2-ObGES expressing plasmid and both the 
geraniol and 10-hydroxygeraniol-producing strains were tested in parallel.  Expression of 
the CrG10H in our geraniol-producing strain resulted in a peak of 5.3 mg/L of 10-
hydroxygeraniol (Figure 10). In addition, compounds inferred to be 10-
hydroxycitronellol and 10-hydroxylinalool by MS analysis were also observed in the 
CrG10H-expressing strain. One of the peaks (Figure 10, Peak 7) was identified as having 
62% probability match for 10-hydroxylinalool (NIST08 MS library), while the identity of 
10-hydroxycitronellol (Figure 10, Peak 9) was inferred from (i) the presence of the 154 
m/z daughter ion (M+ 172 m/z with loss of water as -18 m/z) and a match to previously 
reported MS spectra [83];  (ii) its retention time relative to 10-hydroxylinalool and 10-
hydroxygeraniol and how its elution time relative to citronellol concords with those of 
geraniol and linalool and their corresponding hydroxylated products (Figure 10A) and; 
(iii) its signal profile over time and how it tracks with that of 10-hydroxygeraniol in a 
similar fashion to the way that citronellol tracks with geraniol (Figure 10C). The presence 
of both the proposed 10-hydroxylinalool and 10-hydroxycitronellol in the CrG10H-
expressing strain suggests that this enzyme is promiscuous and can hydroxylate a range 
of monoterpenes. Phenylethanol and tyrosol were detected at comparable levels in all 
strains including wild-type controls with pMevL or pMevH (data not shown). These fusel 
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alcohols are standard yeast metabolites with no relation to the MIA pathway[83,84]  
 
 
Figure 10: Production of monoterpenoids from geraniol-producing strains without 
(-CrG10H) and with (+CrG10H) heterologous expression of C.roseus geraniol 10-
hydroxylase A. Representative total ion chromatographic profiles of monoterpenoids 
extracted from culture broths. Peak identifications using analytical standards are as 
follows: 1, linalool; 3, citronellol; 4, geraniol; 5, mevalonate; 6, eugenol (internal 
 44 
standard); 10, 10-hydroxygeraniol. Peak 7 was identified by NIST08 MS Search 7.0 as a 
62% probability match for 10-hydroxylinalool. Unknown peak 9 is proposed to be 10-
hydroxycitronellol. Peaks 2 and 8 correspond to phenylethanol and tyrosol, respectively, 
which were found to accumulate in all samples, including wild-type controls with pMevL 
or pMevH (not shown). These fusel alcohols are standard yeast metabolites with no 
relation to the MIA pathway. B. Representative EI-MS spectra of 10-hydroxygeraniol 
(peak 10) and peaks proposed to correspond to 10-hydroxycitronellol (peak 9) and 10-
hydroxylinalool (peak 7). Asterisks identify the M+-18 peak. C. Monoterpenoid 
production profiles from geraniol-producing strains without (-CrG10H) or with 
(+CrG10H) co-expression of the geraniol 10-hydroxylase. Error bars represent the 95 % 
confidence interval from triplicate cultures inoculated from a single colony. Note: This 
experiment performed by Nick Gold and Philippe Bauchart. 
 
4.3 The Iridoid Synthase CrIS is a Promiscuous Reductase 
 
After successful synthesis of 10-hydroxygeraniol in yeast, we sought to extend the 
pathway to 10-oxogeranial by the co-expression of the C. roseus 10-hydroxygeraniol 
oxidoreductase (Cr10HGO) in our 10-hydroxygeraniol-producing strain. Although 
depletion of 10-hydroxygeraniol was observed indicating that the CrHGO was active in 
this strain, we were unable to detect 10-oxogeranial or 10-hydroxygeranial. Difficulty in 
measuring 10-oxogeraniol was probably due to its highly reactive aldehyde group. To get 
around this problem, we opted to extend the Iridiod pathway with the addition of the C. 
roseus Iridiod synthase (CrIS) to produce nepetalactol. Surprisingly, nepetalactol, 
geraniol or 10-hydroxygeraniol was not detected but instead a striking 200 mg/L of 
citronellol and 5.6 mg/L of proposed 10-hydroxycitronellol were observed (Figure 11A). 
Based on these results, we speculated that CrIS, which is an NADPH-dependent 
reductive cyclase, might be capable of reducing geraniol and 10-hydroxygeraniol without 
cyclizing them. In addition, the CrIS is known to be promiscuous for a number of 
monoterpenes [86]. To test this hypothesis lysates from yeast expressing the CrIS alone 
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were incubated with geraniol and NADPH. As expected, lysates of cells expressing the 
CrIS produced 10.6 times more citronellol than the negative control when incubated in 
the presence of geraniol and 3.1 times more proposed 10-hydroxycitronellol when 
incubated in the presence of 10-hydroxygeraniol (Figure 11B and 11C), further 
supporting the identity of unknown peak 7 (Figure 10) as 10-hydroxycitronellol. The 
presence of citronellol and 10-hydroxycitronellol in the control lysates is likely due to the 
endogenous yeast proteins Oye2 and Oye3, which are reductases that are known to be 
active on geraniol [87]. By comparing these enzyme assays to the in vivo data (Figure 
11A) we concluded that CrIS outcompetes CrG10H for geraniol and that CrG10H is 
equally poor at converting citronellol to 10-hydroxycitronellol as OYE2/OYE3 is at 
converting 10-hydroxygeraniol to 10-hydroxycitronellol. Furthermore, our results suggest 
that Cr10HGO is active on 10-hydroxycitronellol since its concentration went down only 
in our Cr10HGO-expressing strain (Figure 10A and Figure 11A). These experiments 
provide direct evidence that CrIS is capable of reducing geraniol to citronellol and 10-
hydroxygeraniol to 10-hydroxycitronellol thereby diverting carbon away from the desired 




Figure 11: Evidence of promiscuity of CrIS A. Citronellol (CIT) and 10-
hydroxycitronellol (CIT-OH) production by 10-hydroxygeraniol-producing strain co-
expressing either Cr10HGO (-CrIS) or Cr10HGO-CrIS (+CrIS). B. Percentage of 
geraniol (GER) converted to citronellol (CIT) when incubated with lysates from wild-
type yeast (-CrIS, empty vector) or lysates from yeast cells expressing CrIS (+CrIS) C. 
Percentage of 10-hydroxygeraniol (GER-OH) converted to 10-hydroxycitronellol 
(proposed; CIT-OH) when incubated with lysates from wild-type yeast (-CrIS, empty 
vector) or lysates from yeast cells expressing CrIS (+CrIS). Error bars represent the 95 % 




4.4 In vitro enzyme activity of Cr10HGO-CrIS enzyme pair 
 
In order to demonstrate that the Cr10HGO-CrIS enzyme pair is active in S. cerevisiae, 
we tested lysates of cells expressing both enzymes for the production of nepetalactol 
using 10-hydroxygeraniol as a substrate. Since CrIS catalyzes an irreversible reaction, 
nepetalactol was expected to accumulate even with a low turnover rate. In addition, this 
strategy avoided the issue caused by CrIS activity on geraniol. Lysates expressing both 
Cr10HGO and CrIS did indeed produce nepetalactol from 10-hydroxygeraniol whereas 
control lysates from cells only expressing the Cr10HGO did not (Figure 12). These 
results confirm the functionality of these enzymes in S. cerevisiae as well as their 
concerted activity in the synthesis of nepetalactol [60] and further support the conclusion 
that the absence of in vivo nepetalactol synthesis from our 10-hydroxygeraniol-producing 




Figure 12: 10-hydroxygeraniol oxidase and iridodial synthase enzyme assays A. 
Selected ion monitoring (135 and 168 m/z) chromatograms for assays with 10-
hydroxygeraniol and NAD+ using cell lysates for yeast strains expressing only Cr10HGO 
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(-CrIS) or both Cr10HGO and CrIS (+CrIS). Peaks were identified using analytical 
standards are as follows: 1, nepetalactol; 2, eugenol; 3, 10-hydroxygeraniol. B. MS 
spectra of peak 1 from +CrIS lysate compared with authentic nepetalactol standard. 
 
4.5 In vivo Characterization of Protein-Protein Binding Domains. 
 
Protein scaffolds were investigated as a potential method of improving metabolic flux 
within the MIA pathway. As a first step, 5 protein-protein binding domains were selected 
for testing based on their size, binding affinity and specificity (SYNZIP1, SYNZIP3, 
GBD, SH3 and GHF). These were functionally tested in yeast using a split Venus 
protein-protein interaction assay, where The N and C terminal fragments of a split Venus 
protein were fused to each protein binding domain and its cognate ligand. Successful 
binding in vivo was expected to reconstitute a fluorescent signal. A full version of the 
Venus protein, as well as Venus fragments lacking protein fusions (NVstop and CVstop) 
were used as a control.  The results indicate that all domains successfully bound in vivo 
(Figure 13), as all domains fluoresced significantly more than associated control. The 
best domains were SYNZIP1/2 and SYNZIP3/4, which is unsurprising as these have been 
synthetically designed for high binding affinities [71]. We used this data to select 
SYNZIP3/4, GBD and SH3 for use in future protein scaffolding experiments. 
SYNZIP1/2 was excluded due to its documented cross-reactivity with SYNZIP3/4 [71], 
and GBD and SH3 were selected due to their well documented use in previous 







Figure 13: Split Venus protein-protein interaction assay.  Five domains (SH3, GBD, SYNZIP1/2, 
SYZIP3/4 as well as GHF) were tested. A fully reconstituted Venus protein (green) as 
well as Venus fragments expressed without 3’ protein fusions (red) were used as controls. 
 
4.6 Enhanced Production of MIA Metabolites using Protein Scaffolds.   
 
After validating that protein-protein binding occurred effectively in vivo, we sought to 
demonstrate the functional co-localization of MIA enzymes to a protein scaffold. The 
logical choice for this would have been the three steps covering the conversion of 
geraniol to iridodial that are vulnerable to attack by IS. At the time we were designing 
these experiments however, we were unaware of this activity and chose a different set of 
enzymes to scaffold. ERG20K197E, GES, and old yellow enzyme 2 (OYE2) were used as 
candidates, which together catalyze the formation of citronellol from GPP (Figure 14). As 
GPP causes heavy feedback inhibition to mevalonate kinase (Ki=0.25 μM) its quick 
consumption through scaffolding should improve overall flux through the pathway.  
Furthermore, GPP is highly vulnerable intermediate and can be converted to both FPP 
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and linalool. By using citronellol as an end product, we hoped to avoid the toxicity 




Figure 14: Depiction of citronellol based scaffolding experiments. A. The enzymes 
ERG20K197E, GES and OYE2 are shown fused to their respective binding ligands, which 
are recruited to the scaffold B. Overview of the portion of the pathway being scaffolded, 




























Functional tests were performed by fusing the binding ligands SYN4, GBD(ligand) and 
SH3(ligand) to ERG
K197E, GES, and OYE2 respectively.  ERG20K197E-SYN4 and GES-
GBD(ligand) were expressed on PGREG504(trp) vector and OYE2-SH3(ligand) was 
expressed on a pGREG506(ura) vector.  Four variants of protein scaffold were built with 
architecture consisting of SYN3-(GBD)x-SH3 on a PGREG503(his) vector, where x=1-3. 
Varying the number of GBD domains controls how many copies of GES are recruited to 
the scaffold, and should impact the rate at which GPP is metabolized.  Domains were 
linked together by using a flexible glycine-serine linker with the amino acid sequence 
GGGSGGGSG, as used in other works [67]  Each scaffold, along with the ERG-SYN4-
GES-GBD(ligand) and OYE2-SH3(ligand) plasmids were transformed into an ERG20
K197E 
quadruple auxotroph expressing the pMevL plasmid.  Strains were grown in triplicate and 
analyzed by GC-MS every 12 hours for the production of citronellol, geraniol, 













             
Figure 15: Production of monoterpenes and mevalonate in the presence of different 
scaffolds. Specific titers of geraniol, citronellol, mevalonate and linalool are shown for 
scaffolds possessing 1 (blue), 2(black) and 3(red) GBD domains as well as for the 


































































































































The results of this experiment indicated that monoterpene production was highly 
dependent on scaffold architecture. In general, scaffolds with more GBD domains tended 
to be the most effective. The lowest citronellol producer was the SYN3-(GBD)1-SH3 
scaffold  at 2.72mg/L. The variant with two SYN3-(GBD)2-SH3 was slightly better, 
producing  4.03mg/L citronellol, though this was still slightly less than the un-scaffolded 
control (4.07mg/L).  This suggests that association with the protein scaffold may reduce 
the processivity of some enzymes. The best strain was with the scaffold possessing three 
GBD domains, which produced 6.46mg/L citronellol, a 57.8% increase relative to the 
control. Production of all monoterpenes was also higher in this strain vs. the control 
(57.8% increase for citronellol, 75.6% increase for geraniol, 44.7% increase for linalool).  
The increase in linalool was unexpected as higher producing geraniol/citronellol strains 
would be expected to have less GPP available to form linalool. Mevalonate levels were 
generally inversely proportional to the total monoterpene content 
(geraniol+linalool+cintrollol), with the best producer registering 21.86% less mevalonate 
the control, and 39.6% less than the lowest (monoterpene) producer. This was expected 
as reduced mevalonate indicates alleviation of feedback inhibition, and should be 
associated with higher monoterpene content. No significant growth differences were 
observed between any of the strains.  
 
5. DISCUSSION  
 
5.1 Improvement of Monoterpene Production 
 
With the goal of developing a platform for strictosidine biosynthesis, we initially aimed 
to engineer geraniol production in S. cerevisiae. Our strategy consisted of replacing the 
wild-type ERG20 with the erg20K197E mutant allele combined with over-expression of the 
rate-limiting steps of the mevalonate pathway as well as GPP and geraniol synthases. In 
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previous reports, strains harboring the erg20K197E mutation showed reduced FPP synthase 
activity, and favored monoterpenoid production with strains producing up to 0.455 mg/L 
geraniol [52]. The introduction of a plant geraniol synthase was also demonstrated to 
improve yields of monoterpenoids.  For example, expression of the O. basilicum GES in 
an erg20K197E background resulted in the production of a 10-fold higher monoterpenoid 
titer of 5 mg/L [79,87] Lastly, overexpression of enzymes from the endogenous 
mevalonate can give further improvement to geraniol titers. Our final engineered strain 
produced 11.4 mg/L, a titer that is ~3 fold lower than previously reported for a similarly 
engineered geraniol-producing yeast strain. The difference between these values could be 
due to their over-expression of IDI1 and MAF1 and the fact that a different variant of the 
erg20K mutant was used (erg20K197G instead of erg20K197E ) which may have lead to higher 
titers at the cost of lower cell growth [80]. Aside from geraniol, we also observed the 
related monoterpenoids linalool and citronellol. In S. cerevisiae, the old yellow enzymes 
OYE2 and OYE3 are thought to be responsible for non-specific reduction of geraniol to 
citronellol [57]. In our top geraniol-producing strain the ratio of citronellol to geraniol 
was 0.3, pointing to the fact that this reaction may account for an important drain on the 
carbon in the pathway unless it is deleted from the strain, as previously shown [66]. The 
other major monoterpenoid, limonene, is a direct dephosphorylation product of GPP and 
was only observed in the strains pMevL, erg20K197E and pMevL, pGer, erg20K197E where 
their ratio of linalool to geraniol were 0.28 and 0.15, respectively (Figure 9). Mevalonate 
was also measured since it is known to accumulate due to the inhibition of mevalonate 
kinase by GPP [48] making it a potential indicator of intracellular GPP pools.  We 
observed that our strain engineered to stop at the intermediate GPP (pMevL, erg20K197E) 
also produced the highest mevalonate titer and that mevalonate accumulation could be 
reduced, but not eliminated, by the additional expression of GES (pMevL, pGer, 
erg20K197E) (Figure 9). This is expected as GES consumes GPP but also points to the fact 
that the conversion of GPP to geraniol is likely limiting flux in these strains.  
 
5.2 G10H expression and activity  
 
 56 
The geraniol-producing strain we engineered was used as a starting point for further 
extension of the Iridiod pathway. We first showed that the additional expression of the C. 
roseus geraniol 10-hydroxylase to this strain resulted in the accumulation of 5.3 mg/L of 
10-hydroxygeraniol, a 46.3% turnover of geraniol. In addition, we observed two 
additional hydroxylated monoterpenoids and postulated that they were a product of 
CrG10H. CrG10H activity has been reported on both linalool and citronellol therefore 
this is extremely probable. However, it is possible that some of the 10-hydroxycitronellol 
observed in this strain is a product of OYE2/OYE3 acting on 10-hydroxygeraniol. 
 
5.3 Impact of Iridiod synthase on Metabolite Distribution 
 
Upon further extension of the pathway by co-expression of 10-hydroxygeraniol 
oxidoreductase and Iridiod synthase, we expected to observe iridodial produced from 10-
hydroxygeraniol.  However, only large amounts of citronellol and some putative 10-
hydroxycitronellol with no other monoterpenoids were detected. Since this phenomenon 
was not observed with the expression of 10HGO alone, we hypothesized that the Iridiod 
synthase might be responsible by reducing geraniol to citronellol. The Iridiod synthase is 
a reductive cyclase and although citronellol is not a cyclic product, we theorized that 
these two functions could be decoupled with reduction occurring independently of 
cyclization. We confirmed this activity in vitro by incubating IS-expressing yeast lysates 
with geraniol (Figure 11).  A similar result was observed using 10-hydroxygeraniol 
although IS seems to have lower activity on this substrate. This observation is consistent 
with previous data, which has shown that IS is highly promiscuous and is active on at 
least five other monoterpenoids [86]. Most tellingly, IS retains 90% of its activity on 
citral – the aldehyde analog of geraniol [86]. It is therefore not surprising that IS would 
also have strong activity on geraniol itself.  The observation has serious implications for 
the reconstitution of the Iridiod pathway in yeast.  
 
In spite of the significant hurdles caused by side product reactions at several steps in the 
pathway, Brown et al. were recently successful at producing trace amounts of 
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strictosidine in yeast from glucose [66]. By supplementing cultures with intermediates at 
progressively lower steps in the pathway, they identified geraniol as the failure point as 
supplementing this intermediate to the cells did not produce strictosidine. This bottleneck 
was solved by the expression of additional copies of G10H, which lead to the production 
of small amounts of strictosidine [66]. In light of our results, we postulate that over-
expression of the G10H by Brown et al. resulted in geraniol hydroxylation reaction 
outcompeting reduction by IS thereby channeling flux towards nepetalactol as opposed to 
citronellol. G10H has also been documented to catalyze an irreversible oxidation of 10-
hydroxygeraniol [90], which might further contribute to its success in overcoming the 
geraniol bottleneck. 
 
In addition to unwanted reductase activity from the IS, endogenous S. cerevisiae enzymes 
such as the reductase OYE2 and acetyltransferase Aft1 are known to degrade geraniol 
[57]. Of the two, OYE2 is the most active with its deletion resulting in 60% less geraniol 
degradation in yeast compared to Aft1 with its deletion resulting in only a 7% reduction.  
Brown et al. saw a six-fold increase in strictosidine when they deleted these two genes 
[66]. By contrast, we saw no citronellol produced in our 10-hydroxygeraniol-producing 
strain expressing 10HGO (Figure 12A) indicating that OYE2 and OYE3 were not very 
active in our strain or that they were outcompeted by the CrG10H-Cr10HGO enzyme 
pair. Furthermore, our enzyme assay data using yeast crude lysates indicated that IS was 
~10 times more potent at reducing geraniol than OYE2 and OYE3 combined and is 
probably the biggest drain on the pathway in our strain.   
 
5.4 Enzyme Co-localization and the MIA Pathway 
 
The unwanted activity of IS on geraniol and 10-hydroxygeraniol is a major barrier to 
reconstituting this pathway in yeast. There are many possible ways to solve this problem 
including protein engineering, promoter swapping as well as synthetic enzyme co-
localization methods. We chose to investigate protein scaffolds as a solution, which can 
physically sequester enzymes together to improve turnover and reduce vulnerability to IS 
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[91]. This strategy has been successfully used in other works, and has been documented 
to improve product yields up to 77 fold [67].    We begun by characterizing a set of 5 
protein-protein binding domains selected from existing literature using a split Venus 
protein complementation assay. The results indicated that all domains successfully bound 
their ligands, with GBD, SYNZIP1/2 and SYNZIP3/4 being the most effective. We then 
showed we could redirect flux in the MIA pathway by scaffolding a section of the 
pathway spanning from GPP to citronellol. The base scaffold had an architecture 
consisting of SYN3-(GBD)x-SH3 and the number of GBD domains used varied from 1-3.  
Altering the number of GBD domains changes the enzymatic stoichiometry of the 
scaffold, with more GBD domains recruiting more copies of GES and increasing GPP 
turnover. Scaffold effectiveness did indeed prove to be proportional to the number of 
GBD domains used, with (GBD)3 producing 117% more citronellol than (GBD)1 and 
57.8% more citronellol relative to the unscaffolded control. So far only one other 
scaffolding experiment has been done in yeast, where the authors targeted resveratrol 
biosynthesis, and managed to improve the yield of that product five fold [68]. While our 
improvements were more modest, the efficiency of the scaffold is expected to be highly 
case-specific and is dependent on the architectural configuration of the entire macro-
protein complex. In this case, the reduced efficiency of the SYN3-(GBD)1-SH3 scaffold 
relative to the control suggests that association with this scaffold may reduce the 
processivity of some or all of these enzymes. Despite this, the split-Venus interaction 
assay and successful functional tests on citronellol indicate that protein scaffolds are a 
useful tool for directing metabolic flux in Saccharomyces cerevisiae. Future work will 
focus on targeting the section of the pathway spanning from geraniol to iridodial, which 





MIAs of medicinal value have very complex structures that require long biosynthesis 
pathways.  For example, strictosidine undergoes 6 to 8 proposed enzymatic steps to form 
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catharanthine and/or tabersonine, while 7 enzymatic steps [64] convert tabersonine to 
vindoline and a peroxidase may be involved in the assembly of -3’,4’-
anhydrovinblastine from catharanthine and vindoline [92]. Recently, a prototype 7 step 
pathway was assembled in yeast to that converted tabersonine to several pathway 
intermediates and to vindoline. The results presented in this and in other studies [66,86]  
suggest that a very efficient strictosidine pathway together with more efficient 
downstream steps [64] will be necessary in order to reach meaningful titers of different 
MIAs in yeast. In this work we assembled a pathway for the synthesis of the Iridiod 
nepetalactol in yeast and dissected its carbon distribution thereby identifying 
promiscuous reactions from G10H and IS that severely impede flux through the pathway.  
As a first step towards solving this problem, we also demonstrated that protein scaffolds 
could be used to direct metabolic flux within the MIA pathway.  We showed that 
scaffolds could be used to improve citronellol by 57.8%, which serves as an excellent 
proof of concept towards their use in improving the function of IS sensitive enzymes. 
This information will be vital for further work on the reconstruction and optimization of 
MIA biosynthesis pathways in yeast.  
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